BNP Paribas Asset Management
SLNO

BNP Paribas Asset Management’s Soleno Therapeutics SLNO Stock Holding History

BNP Paribas Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-57,828
Closed -$1.94M – 2333
2026
Q1 		$1.94M Buy
57,828
+18,870
+48% +$740K ﹤0.01% 1079
2025
Q4 		$1.8M Buy
38,958
+38,559
+9,664% +$2.11M ﹤0.01% 1081
2025
Q3 		$27K Buy
399
+73
+22% +$5.41K ﹤0.01% 1282
2025
Q2 		$27K Buy
+326
New +$24.4K ﹤0.01% 1390

BNP Paribas Asset Management's SLNO Position: Q2 2026 in Review

BNP Paribas Asset Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 57,828 shares — an estimated $1.94M sold.

BNP Paribas Asset Management first reported a position in SLNO in Q2 2025 and held it in 4 quarters. The position peaked at $1.94M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • BNP Paribas Asset Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • BNP Paribas Asset Management sold 57,828 Soleno Therapeutics shares in Q2 2026, an estimated $1.94M.
  • BNP Paribas Asset Management first reported a position in Soleno Therapeutics in Q2 2025 and held it in 4 quarters.
  • BNP Paribas Asset Management's Soleno Therapeutics position peaked at $1.94M in Q1 2026.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.